Literature DB >> 17555467

Limited influence of UGT1A1*28 and no effect of UGT2B7*2 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes.

Vincent C Peterkin1, Jonathan N Bauman, Theunis C Goosen, Lee Menning, Michael Z Man, Joseph D Paulauskis, J Andrew Williams, Scott P Myrand.   

Abstract

AIMS: UGT1A1 and UGT2B7 are enzymes that commonly contribute to drug glucuronidation. Since genetic factors have been suggested to contribute to variability in activities and expression levels of these enzymes, a quantitative assessment of the influence of the major genotypes (UGT1A1*28 or UGT2B7*2) on enzyme activities was conducted.
METHODS: Using a bank of microsomal samples from 59 human livers, the effect of UGT1A1*28 or UGT2B7*2 polymorphisms were investigated on rates of estradiol 3-glucuronidation (a marker of UGT1A1 enzyme activity) or zidovudine glucuronidation (a marker of UGT2B7 enzyme activity) and levels of immunoreactive protein for each enzyme. Glucuronidation rates for both enzymes were measured at K(m)/S(50) and 10 times K(m)/S(50) concentrations.
RESULTS: UGT1A1 and UGT2B7 enzyme activities varied up to 16-fold and sixfold, respectively. Rates at K(m)/S(50) concentration closely correlated with rates at 10 times K(m)/S(50) concentration for both enzymes (but not at 1/10th K(m) for UGT2B7). Enzyme activities correlated with relative levels of immunoreactive protein for UGT1A1 and UGT2B7. Furthermore, rates of zidovudine glucuronidation correlated well with rates of glucuronidation of the UGT2B7 substrate gemcabene, but did not correlate with UGT1A1 enzyme activities. For the UGT1A1*28 polymorphism, consistent with levels of UGT1A1 immunoreactive protein, mean UGT1A1 activity was 2.5- and 3.2-fold lower for TA(6)/TA(7) (P < 0.05) and TA(7)/TA(7) (P < 0.001) genotypes in comparison with the TA(6)/TA(6) genotype.
CONCLUSIONS: Relative to the observed 16-fold variability in UGT1A1 activity, these data indicate only a partial (approximately 40%) contribution of the UGT1A1*28 polymorphism to variability of interindividual differences in UGT1A1 enzyme activity. For the UGT2B7*2 polymorphism, genotype had no influence on immunoreactive UGT2B7 protein or the rate of 3'-azido-3'-deoxythymidine glucuronidation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17555467      PMCID: PMC2048551          DOI: 10.1111/j.1365-2125.2007.02923.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  26 in total

1.  Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone.

Authors:  Jean Thibaudeau; Johanie Lépine; Jelena Tojcic; Yannick Duguay; Georges Pelletier; Marie Plante; Jacques Brisson; Bernard Têtu; Simon Jacob; Louis Perusse; Alain Bélanger; Chantal Guillemette
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

2.  So many studies, too few subjects: establishing functional relevance of genetic polymorphisms on pharmacokinetics.

Authors:  J Andrew Williams; Keith Johnson; Joseph Paulauskis; Jack Cook
Journal:  J Clin Pharmacol       Date:  2006-03       Impact factor: 3.126

3.  In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction.

Authors:  Andrew Rowland; David J Elliot; J Andrew Williams; Peter I Mackenzie; Ronald G Dickinson; John O Miners
Journal:  Drug Metab Dispos       Date:  2006-03-24       Impact factor: 3.922

4.  Successful treatment of severe unconjugated hyperbilirubinemia via induction of UGT1A1 by rifampicin.

Authors:  Ewa Ellis; Martin Wagner; Frank Lammert; Antal Nemeth; Judith Gumhold; Christian P Strassburg; Christian Kylander; Despina Katsika; Michael Trauner; Curt Einarsson; Hanns-Ulrich Marschall
Journal:  J Hepatol       Date:  2005-10-27       Impact factor: 25.083

Review 5.  UDP-glucuronosyltransferases and clinical drug-drug interactions.

Authors:  Tony K L Kiang; Mary H H Ensom; Thomas K H Chang
Journal:  Pharmacol Ther       Date:  2005-01-12       Impact factor: 12.310

6.  Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance.

Authors:  C R Bhasker; W McKinnon; A Stone; A C Lo; T Kubota; T Ishizaki; J O Miners
Journal:  Pharmacogenetics       Date:  2000-11

7.  Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank.

Authors:  M B Fisher; M Vandenbranden; K Findlay; B Burchell; K E Thummel; S D Hall; S A Wrighton
Journal:  Pharmacogenetics       Date:  2000-11

8.  The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver.

Authors:  Hugo Girard; Lyne Villeneuve; Michael H Court; Louis-Charles Fortier; Patrick Caron; Qin Hao; Lisa L von Moltke; David J Greenblatt; Chantal Guillemette
Journal:  Drug Metab Dispos       Date:  2006-04-04       Impact factor: 3.922

9.  UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations.

Authors:  J W Lampe; J Bigler; N K Horner; J D Potter
Journal:  Pharmacogenetics       Date:  1999-06

10.  Prevalence of polymorphisms in the human UDP-glucuronosyltransferase 2B family: UGT2B4(D458E), UGT2B7(H268Y), and UGT2B15(D85Y).

Authors:  J W Lampe; J Bigler; A C Bush; J D Potter
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-03       Impact factor: 4.254

View more
  19 in total

1.  A quantitative framework and strategies for management and evaluation of metabolic drug-drug interactions in oncology drug development: new molecular entities as object drugs.

Authors:  Karthik Venkatakrishnan; Michael D Pickard; Lisa L von Moltke
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

2.  Effect of rifampin and rifabutin on the pharmacokinetics of lersivirine and effect of lersivirine on the pharmacokinetics of rifabutin and 25-O-desacetyl-rifabutin in healthy subjects.

Authors:  Manoli Vourvahis; John Davis; Rong Wang; Gary Layton; Heng Wee Choo; Chew-Lan Chong; Margaret Tawadrous
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

Review 3.  Clinical pharmacology--providing tools and expertise for translational medicine.

Authors:  J K Aronson; A Cohen; L D Lewis
Journal:  Br J Clin Pharmacol       Date:  2008-02       Impact factor: 4.335

4.  UGT2B gene expression analysis in multiple tobacco carcinogen-targeted tissues.

Authors:  Nathan R Jones; Philip Lazarus
Journal:  Drug Metab Dispos       Date:  2014-01-23       Impact factor: 3.922

5.  Utility of Pretreatment Bilirubin Level and UGT1A1 Polymorphisms in Multivariate Predictive Models of Neutropenia Associated with Irinotecan Treatment in Previously Untreated Patients with Colorectal Cancer.

Authors:  Luis Parodi; Eve Pickering; Laura A Cisar; Doug Lee; Raoudha Soufi-Mahjoubi
Journal:  Arch Drug Inf       Date:  2008-12

6.  Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation.

Authors:  Awewura Kwara; Margaret Lartey; Isaac Boamah; Naser L Rezk; Joseph Oliver-Commey; Ernest Kenu; Angela D M Kashuba; Michael H Court
Journal:  J Clin Pharmacol       Date:  2009-07-23       Impact factor: 3.126

7.  Effects of UGT1A1*28 polymorphism on raloxifene pharmacokinetics and pharmacodynamics.

Authors:  Jurij Trontelj; Janja Marc; Andrej Zavratnik; Marija Bogataj; Ales Mrhar
Journal:  Br J Clin Pharmacol       Date:  2009-04       Impact factor: 4.335

8.  Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system.

Authors:  Michael H Court
Journal:  Drug Metab Rev       Date:  2010-02       Impact factor: 4.518

9.  Influence of valproic acid concentration and polymorphism of UGT1A4*3, UGT2B7 -161C > T and UGT2B7*2 on serum concentration of lamotrigine in Chinese epileptic children.

Authors:  Limin Liu; Limei Zhao; Qiuning Wang; Feng Qiu; Xiujun Wu; Yanan Ma
Journal:  Eur J Clin Pharmacol       Date:  2015-08-26       Impact factor: 2.953

10.  Serum bilirubin levels on ICU admission are associated with ARDS development and mortality in sepsis.

Authors:  R Zhai; C C Sheu; L Su; M N Gong; P Tejera; F Chen; Z Wang; M P Convery; B T Thompson; D C Christiani
Journal:  Thorax       Date:  2009-05-28       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.